000			01945 a2200517 4500
005			20250515165445.0
264		0	_c20090827
008			200908s 0 0 eng d
022			_a1029-2403
024	7		_a10.1080/10428190902856808 _2doi
040			_aNLM _beng _cNLM
100	1		_aStopeck, Alison T
245	0	0	_aA phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108. _h[electronic resource]
260			_bLeukemia & lymphoma _cMay 2009
300			_a728-35 p. _bdigital
500			_aPublication Type: Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aAngiogenesis Inhibitors _xadministration & dosage
650	0	4	_aAntibodies, Monoclonal _xadministration & dosage
650	0	4	_aAntibodies, Monoclonal, Humanized
650	0	4	_aBevacizumab
650	0	4	_aBiomarkers _xanalysis
650	0	4	_aDisease-Free Survival
650	0	4	_aHumans
650	0	4	_aLymphoma, Large B-Cell, Diffuse _xdrug therapy
650	0	4	_aLymphoma, Mantle-Cell _xdrug therapy
650	0	4	_aLymphoma, Non-Hodgkin _xdrug therapy
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aReceptors, Vascular Endothelial Growth Factor _xanalysis
650	0	4	_aSalvage Therapy _xmethods
650	0	4	_aSouthwestern United States
650	0	4	_aVascular Cell Adhesion Molecule-1 _xblood
700	1		_aUnger, Joseph M
700	1		_aRimsza, Lisa M
700	1		_aBellamy, William T
700	1		_aIannone, Maria
700	1		_aPersky, Daniel O
700	1		_aLeblanc, Michael
700	1		_aFisher, Richard I
700	1		_aMiller, Thomas P
773	0		_tLeukemia & lymphoma _gvol. 50 _gno. 5 _gp. 728-35
856	4	0	_uhttps://doi.org/10.1080/10428190902856808 _zAvailable from publisher's website
999			_c18805314 _d18805314